Compare BIO & MTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | MTZ |
|---|---|---|
| Founded | 1952 | 1929 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Water Sewer Pipeline Comm & Power Line Construction |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 15.9B |
| IPO Year | 1994 | 2005 |
| Metric | BIO | MTZ |
|---|---|---|
| Price | $361.70 | $179.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 21 |
| Target Price | ★ $356.67 | $313.67 |
| AVG Volume (30 Days) | 232.9K | ★ 1.8M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 142.61 | ★ 146.12 |
| EPS | ★ 11.25 | 4.32 |
| Revenue | $2,583,200,000.00 | ★ $14,299,171,000.00 |
| Revenue This Year | N/A | $27.87 |
| Revenue Next Year | $1.86 | $17.61 |
| P/E Ratio | ★ $32.60 | $42.33 |
| Revenue Growth | 0.65 | ★ 16.22 |
| 52 Week Low | $236.73 | $147.49 |
| 52 Week High | $396.23 | $441.43 |
| Indicator | BIO | MTZ |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 45.11 |
| Support Level | $354.27 | $164.31 |
| Resistance Level | $392.10 | $203.46 |
| Average True Range (ATR) | 12.87 | 12.58 |
| MACD | -1.34 | 2.14 |
| Stochastic Oscillator | 23.83 | 57.01 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.